

Anti-HLA-DR [1D10 (Hu1D10; Apolizumab)] Bulk Size Ab03369-10.3-BT

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

Isotype and Format: Human IgG1, Fc Silent™, Kappa

Clone Number: 1D10 (Hu1D10; Apolizumab)

Alternative Name(s) of Target: CD74; HLA class II histocompatibility antigen gamma chain; HLA-DR antigens-associated invariant chain; Ia antigen-associated invariant chain; Ii; p33

UniProt Accession Number of Target Protein: P04233

Published Application(s): IP, therapeutic, FC

Published Species Reactivity: Human

Immunogen: The original mouse antibody 1D10 was generated by immunizing female BALB/c mice intraperitoneally with human large cell lymphoma HO-85. Humanized version of this antibody was generated by grafting CDRs of the parental mouse antibody onto human framework regions.

Specificity: This antibody recognizes a variant epitope on the beta chain of HLA-DR. It can bind some but not all HLA-DR beta chains. The antigen that this antibody binds is expressed on lymphocytes, macrophages, and dendritic (mesenchymal) cells and on most B cell neoplasms. HLA-DR is an MHC class II cell surface receptor encoded by the human leukocyte antigen complex on chromosome 6 region 6p21.31. HLA-DR is also involved in several autoimmune conditions, disease susceptibility and disease resistance. The primary function of HLA-DR is to present peptide antigens, potentially foreign in origin, to the immune system for the purpose of eliciting or suppressing T-(helper)-cell responses that eventually lead to the production of antibodies against the same peptide antigen.

Application Notes: This antibody is the humanized version of anti-HLA-DR mouse parental antibody called 1D10. This antibody is capable of recognizing a majority of B-cell malignancies. This antibody is capable of inducing complement-mediated cytotoxicity, antibody dependent cell cytotoxicity and direct apoptosis of B cells expressing HLA-DR. The original mouse version does not possess these characteristics. This antibody has similar affinity to human HLA-DR as compared to its parental mouse antibody (PMID: 11477560). This antibody was also used for the generation of a bispecific antibody in combination with anti-CD3e antibody M291 (Visilizumab) (US6129914).

Antibody First Published in: Kostelny et al. Humanization and characterization of the anti-HLA-DR antibody 1D10. Int J Cancer. 2001 Aug 15;93(4):556-65. [PMID:11477560](#)

Note on publication: This paper describes the generation and characterization of the humanized version

of anti-HLA DR antibody 1D10.

Product Form

Size: 1 mg Purified antibody in bulk size.

Purification: Protein A affinity purified

Supplied In: PBS only.

Storage Recommendation: Store at 4°C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommended this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.